Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look?
Becton, Dickinson and Company (NYSE:BDX) has steady demand for its medical devices, together with a long history of paying ...
Model output · Signal date 2026-10-16
Becton Dickinson & Co (BDX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Bottom 35%
of 5184 stocks scored
Rank correlation · 90D
17.0%
Spearman, 357 dates
Market Cap
$52.23B
large-cap · #4 of 60 peers
Summary
Becton Dickinson & Co (BDX) stock forecast summary
Our AI ranks Becton Dickinson & Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Becton Dickinson & Co is a large-cap company with a market capitalization of $52.23B. It ranks number 4 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For BDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 17.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BDX included.
Follow BDX freePrice
BDX price chart and AI forecast
Cross-section · 2026-10-16
How BDX ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Becton Dickinson & Co (BDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | BDX | Rank |
|---|---|---|
| Market Cap | $52.23B | 4/60 |
| P/E Ratio | 62.26x | 5/25 |
| P/B Ratio | 2.14x | 45/55 |
| Dividend Yield | 2.24% | 2/10 |
| EPS | $3.08 | – |
| Book Value/Share | $89.64 | – |
| Revenue/Share | $73.70 | – |
| FCF/Share | $9.30 | – |
Profitability & Margins
| Metric | BDX | Rank |
|---|---|---|
| ROE | 3.9% | 18/41 |
| ROA | 1.9% | 19/44 |
| ROIC | 4.7% | 21/53 |
| Gross Margin | 46.4% | 45/53 |
| Operating Margin | 9.6% | 20/54 |
| Net Margin | 4.7% | 19/43 |
| EBT Margin | 7.0% | 21/54 |
| Tax Rate | 13.7% | – |
Financial Health
| Metric | BDX | Rank |
|---|---|---|
| Current Ratio | 0.87x | 58/59 |
| Quick Ratio | 0.51x | 54/55 |
| D/E Ratio | 1.08x | 19/56 |
| Financial Leverage | 2.08x | 19/54 |
| Interest Coverage | 1.1x | 22/48 |
| Working Capital | -$1.26B | 59/59 |
Cash Flow
| Metric | BDX | Rank |
|---|---|---|
| Operating Cash Flow | $3.26B | 4/55 |
| Free Cash Flow | $2.53B | 4/50 |
| Capital Spending | -$728M | 46/50 |
| OCF Growth YoY | 0.2% | 22/33 |
| FCF Growth YoY | -0.7% | 18/25 |
| FCF/Sales | 12.6% | 18/49 |
| CapEx/Sales | 3.6% | 24/49 |
Operational Efficiency
| Metric | BDX | Rank |
|---|---|---|
| Asset Turnover | 0.40x | 45/50 |
| Receivables Turnover | 8.5x | 7/51 |
| Inventory Turnover | 3.2x | 14/51 |
| Fixed Assets Turnover | 3.3x | 45/52 |
| Days Sales Outstanding | 43 days | 45/51 |
| Days Inventory | 113 days | 38/51 |
| Payables Period | 207 days | 4/46 |
| Cash Conversion Cycle | -52 days | 39/42 |
Income Statement
| Metric | BDX | Rank |
|---|---|---|
| Total Revenue | $20.07B | 4/52 |
| Operating Income | $1.92B | 5/55 |
| Net Income | $942M | 7/44 |
| R&D Expense | $1.06B | 3/53 |
| SG&A Expense | $5.07B | 3/53 |
| Cost of Goods Sold | $10.75B | 2/53 |
Dividend & Shareholder Information
| Metric | BDX | Rank |
|---|---|---|
| Dividends Per Share | $4.30 | – |
| Payout Ratio | 139.6% | 1/8 |
| Shares Outstanding | 272M | – |
| Net Income Growth | -40.6% | 17/19 |
| EPS Growth | -52.2% | 20/21 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $8.14B | 16.0% of assets |
| Cash & Short-term Investments | $708M | 1.4% of assets |
| Accounts Receivable | $2.36B | 4.7% of assets |
| Inventory | $3.32B | 6.5% of assets |
| Total Liabilities | $26.32B | 51.9% of assets |
| Short-term Debt | $3.30B | 6.5% of assets |
Quarterly Financial Reports
BDX quarterly financials and insider trading
Industry Peers · Surgical & Medical Instruments & Apparatus
Becton Dickinson & Co (BDX) industry peers
Companies classified under the same SEC industry code as Becton Dickinson & Co (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▶ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▼ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▶ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▶ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.08B |
| AORT Artivion, Inc. | ▼ | $1.06B |
| IART Integra Lifesciences Holdings Corp | ▲ | $1.03B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▼ | $882M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▲ | $803M |
| MDXG Mimedx Group, Inc. | ▶ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| SSII Ss Innovations International, Inc. | ▶ | $507M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▲ | $448M |
| CERS Cerus Corp | ▲ | $439M |
| NPCE Neuropace Inc | ▲ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▼ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
Where BDX sits on the market map
Industrial Applications and Services · Surgical & Medical Instruments & Apparatus
News
Becton Dickinson & Co (BDX) stock news
Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?
Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its ...
BDX - Becton, Dickinson and Company
Becton, Dickinson and Company is currently listed on NYSE under BDX. One share of BDX stock can currently be purchased for approximately $187.37. Is Becton, Dickinson and Company (BDX) overvalued or ...
FAQ
Becton Dickinson & Co (BDX) stock forecast FAQ
What is the Becton Dickinson & Co (BDX) stock forecast?
Our AI ranks Becton Dickinson & Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Becton Dickinson & Co stock predictions?
For BDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 17.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Becton Dickinson & Co forecasts updated?
Becton Dickinson & Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Becton Dickinson & Co's industry peers?
60 issuers in our coverage, BDX included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Medline Inc. (MDLN), Resmed Inc (RMD), Dexcom Inc (DXCM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.